INTRODUCTION
============

Total hip and knee arthroplasty (THA and TKA) represent a major advance in the treatment of refractory hip/knee joint pain. TKA and THA are performed very commonly and are projected to increase dramatically in numbers in the next two decades \[[@R1]\]. Increasing longevity, earlier age at arthroplasty, and excellent pain and functional outcomes with these procedures are cited as reasons for the increasing incidence of these procedures. A number of patients, however, have suboptimal outcomes. Complications may include refractory pain, peri-prosthesis osteolysis with aseptic loosening, heterotopic ossification, and infection, which may result in a failed arthroplasty. Evaluation for complications of arthroplasty are primarily clinical, with few prognostic or diagnostic tests easily available that allow early identification of this subgroup of patients with suboptimal outcomes.

Biomarkers are objective indicators of biologic processes, pathologic processes or pharmaceutical responses to therapeutic interventions \[[@R2]\]. A number of studies have assessed the prognostic and diagnostic utility of biomarkers in improving evaluation of outcomes following arthroplasty. The purpose of this systematic review is to summarize the data from the literature regarding biomarkers for arthroplasty outcomes. We specifically evaluated if there are any valid biomarkers for osteolysis or loosening of the prosthesis, prosthetic infections, pain/stiffness following arthroplasty, or other complications following arthroplasty.

METHODS
=======

Study Design
------------

All English language studies investigating biomarkers for various clinical outcomes of arthroplasty in humans were included in this review. Exclusion criteria included case reports, meta-analyses, and reviews. Studies that evaluated short term post-operative changes in biomarkers, biomarker changes related to medical therapies following arthroplasty, thromboembolic outcomes, and studies limited to pathology only were excluded as they were felt to be beyond the scope of this review.

Search Methods for Identification of Studies
--------------------------------------------

A Cochrane librarian searched the MEDLINE electronic bibliographic database up to July 2008 using the MeSH terms "arthroplasty", "replacement" and "biomarkers" and similar terms. The reference lists of identified publications were reviewed to identify any additional studies (Appendix **1** and **2**).

Data Collection
---------------

Two reviewers (MM and JS) independently applied inclusion/exclusion criteria to all potential studies and extracted data and outcomes using a standardized form. Any disagreements were resolved by discussion between the two reviewers, referring to a third party if necessary. Review authors were not blinded to any features of studies, since unblinding has minimal impact on selection bias \[[@R3]\].

From each study, we extracted the following data -- (1) study population, (2) methods and details of any interventions, (3) type of arthroplasty and implant, knee *vs* hip *vs* other, cemented *vs* noncemented, primary *vs* revision, and (4) types of biomarkers evaluated. Outcome data were extracted, where possible, as raw numbers, plus any summary measures where standard deviations or confidence intervals were given. If no raw results were available, specific outcomes were described in detail.

RESULTS
=======

Eligible Studies
----------------

A total of 105 articles met initial criteria from the initial MEDLINE search completed in June 2007. The search was updated in July 2008 and a total of 149 articles were identified (Fig. **[1](#F1){ref-type="fig"}**). A total of 30 studies met inclusion/exclusion criteria, 26 from the original search and four additional studies from the reference lists of these studies.

Osteolysis
----------

A total of five studies evaluated biomarkers for osteolysis following knee or hip arthroplasty (summarized in Table **[1](#T1){ref-type="table"}**). Most comparisons were made to populations with arthroplasty with no osteolysis and to healthy controls without arthroplasty.

### Collagen telopeptides:

Three studies evaluated collagen telopeptides as biomarkers for osteolysis following hip arthroplasty. Antoniou *et al.*\[[@R4]\] reported significantly higher urinary cross-linked N-telopeptides of type-T collagen in patients with osteolysis following hip arthropathy compared to controls. von Schewelov *et al.*\[[@R5]\] found a near significant increase in urinary cross-linked N-telopeptide in the osteolysis versus non-osteolysis group (p=0.06), which became significant after adjusting for age, gender, and time after surgery. Arabmotlagh *et al.*\[[@R6]\] found serum C-terminal telopeptides of type I collagen 3 weeks post-operatively to be significantly correlated with bone loss one year after hip arthroplasty.

### Interleukin-1β (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α):

Neither of the two studies that evaluated serum IL-1 β or TNF-α as a biomarker for osteolysis following hip arthroplasty found a significant difference between patients with osteolysis compared to controls \[[@R7],[@R8]\].

### IL-6:

Two studies \[[@R7],[@R8]\] evaluated IL-6 as a biomarker for osteolysis following hip arthroplasty. Hernigou *et al.*\[[@R8]\] reported significantly higher IL-6 levels in patients with osteolysis compared to controls, while, in contrast, Fiorto *et al.*\[[@R7]\] did not find a significant difference in IL-6 levels with similar comparison groups.

### Other:

Biomarkers evaluated by single studies included bone alkaline phosphatase (bone ALP) and osteocalcin \[[@R6]\]; IL-11, transforming growth factor-beta (TGF-*β*), matrix metalloproteinase-1 (MMP-1) and prostaglandin E-2 (PGE-2) \[[@R7]\]; and C-reactive protein (CRP) \[[@R8]\]. Only IL-11 was significantly lower in patients with osteolysis when compared to healthy controls and those without osteolysis.

Loosening
---------

A total of 14 studies evaluated biomarkers for loosening of the prosthesis following knee or hip arthroplasty compared to healthy controls or patients with non-loosened prostheses (summarized in Table **[2](#T2){ref-type="table"}**). Nine studies evaluated serum biomarkers and five, synovial fluid biomarkers.

Serum Biomarkers
----------------

### Collagen Telopeptides:

Five studies evaluated various collagen peptides as a biomarker for prosthetic loosening. Serum levels of a C-terminal propeptide of type I procollagen (PICP) were not significantly different between clinically loosened hip prosthetic joints and controls \[[@R9]\] or between unfixed *vs* fixed knee protheses \[[@R10]\]. However, Savarino *et al*. \[[@R11]\] demonstrated a significantly lower PICP concentrations in loosened hip prostheses compared to stable hip implants. Serum N-terminal propeptide of type I procollagen (PINP) levels did not differ between patients with hip prostheis loosening and controls \[[@R12]\].

Savarino *et al*. \[[@R11]\] reported significantly higher serum cross-linked N-terminal telopeptide (NTx) levels in loosened hip protheses compared to controls. Li *et al*. \[[@R10]\] found significantly higher levels of serum cross-linked C-terminal telopeptides (ICTP) in unfixed knee arthroplasties when compared to fixed joints. Conversely, Wilkinson *et al*. \[[@R12]\] found no difference in ICTP levels between patients with loosened hip prostheses and controls. Moreschini *et al*. \[[@R13]\] found no significant difference in type III procollagen peptide levels in patients with loosened hip prostheses when compared to controls with osteoarthritis.

Schneider *et al*. \[[@R9]\] and Wilkinson *et al*. \[[@R12]\] both found significantly increased levels of urinary crosslinked N-telopeptides of type I collagen in patients with loosened hip arthroplasty when compared to stable prostheses.

### TNF-α:

Two studies \[[@R14],[@R15]\] evaluated TNF-*α* as a biomarker for loosening of arthroplasty. Hundri-Haspl *et al*. \[[@R15]\] noted significant increase in TNF-*α* values in patients with loosened knee and hip arthroplasty when compared to controls, while Granchi *et al*. \[[@R14]\] found no difference in TNF-*α* levels in similar comparison groups.

### IL-1β:

Three studies \[[@R13]-[@R15]\] evaluated serum IL-1*β* as a biomarker for arthroplasty loosening. Hundri-Haspl *et al*. \[[@R15]\] noted significant increase in IL-1*β* in patients with loosened knee and hip arthroplasty when compared to controls. Granchi *et al*. \[[@R14]\] did not find a difference in IL-1*β* when comparing loosened hip arthroplasty to healthy controls. However, on subgroup analysis, they found a significant increase in IL-1*β* in patients with loosened titaniumaluminium-vanadium (TiAIV) cemented hip prostheses in comparison to healthy controls as well as loosened cobalt-chromium (CrCoMo) hip implants (cemented and uncemented) and uncemented TiAIV implants. Moreschini *et al*. \[[@R13]\] reported detectable IL-1*β* in 4 of 9 patients with loosened hip implants compared to only 1 of 13 patients with fixed hip implant and 0 of 13 patients with OA prior to arthroplasty, though no statistical analysis was performed.

### IL-6:

Two studies \[[@R14],[@R16]\] found no significant differences in IL-6 levels in patients with loosened hip arthroplasty compared to controls.

### Granulocyte-macrophage colony stimulating factor (GM-CSF):

Streich *et al*. \[[@R16]\] demonstrated detectible levels of GM-CSF in only 1 of 23 patients with loosened hip arthroplasty and in 0 of 23 of fixed hip implant patients. Granchi *et al*. \[[@R14]\] reported significantly higher levels of GM-CSF in patients with a loosened hip arthroplasty when compared to healthy controls. This significant increase was demonstrated in all subgroups (cemented/uncemented TiAIV implants, cemented CrCoMo implants) except loosened uncemented CrCoMo implants which were similar to controls.

### Osteocalcin:

Schneider *et al*. \[[@R9]\] reported significantly higher osteocalcin levels in loosened versus stable prostheses, while Wilkinson *et al*. \[[@R12]\] found no difference with the same comparison. Li *et al*. \[[@R10]\] found significantly higher osteocalcin levels in patients with potentially unstable knee prostheses compared to patients with stable implants at 12 months, but no differences were noted at 24 months.

### Bone alkaline phosphatase (ALP):

Bone-specific ALP levels were similar in patients with and without loosening of hip prosthesis in two studies \[[@R9],[@R12]\].

### Urine deoxypyridinoline:

Schneider *et al*. \[[@R9]\] found significantly higher urine deoxypyridinonline levels in patients with loosened hip implants compared to stable implants, while Wilkinson *et al*. \[[@R12]\] reported no significant difference in similar comparison groups.

### IL-2 receptor:

Two studies \[[@R14],[@R16]\] found no significant differences in IL-2 receptor concentrations in patients with prosthesis loosening compared to controls.

### Other:

The evidence for each of the following was based on single studies. Significantly higher levels of osteoprotegerin (OPG) and RANKL \[[@R17]\], hyaluronic acid \[[@R13]\], urine pyridinoline \[[@R9]\] and IL-8 \[[@R15]\] were found in patients with loosened hip implants compared to their respective controls. Elastase levels were not significantly different between patients with loosened implant and controls \[[@R16]\].

Synovial Biomarkers
-------------------

Four studies evaluated various biomarkers in synovial fluid as a marker for loosening of the prosthetic joint when compared to controls.

### IL-1β:

Nivbrant *et al*. \[[@R18]\] found significantly higher synovial *IL-1β*in loosened hip implants compared to osteoarthritis patients, but were similar to patients with fixed hip prostheses. Similarly, Kovacik *et al.*\[[@R19]\] reported significantly higher synovial *IL-1β*levels in patients with loosened knee prostheses compared to osteoarthritis patients.

### Other:

Nivbrant *et al*. \[[@R18]\] demonstrated significantly higher synovial TNF-α levels in loosened prosthetic hip joints when compared to OA patients, though not when compared to fixed hip implants. Synovial IL-6 levels were similar between all of these groups, though too few observations were available for comparisons. Kawasaki *et al*. \[[@R20]\] noted significantly higher YKL-40 levels, a growth factor for chondrocytes and fibroblasts, in failed hip implants when compared to OA patients, though these levels were similar to patients with osteonecrosis of the hip. Other biomarkers found to be significantly elevated in loosened prostheses when compared to OA patients in single studies were TNF-related activation protein (TRAP) concentrations \[[@R19]\], IL-8 \[[@R21]\], and IL-10 \[[@R21]\]. Lower concentrations of osteocalcin, B-crosslaps, and bone ALP were also noted in loosened hip prostheses when compared to OA patients in a single study \[[@R21]\]. IL-1α concentrations were similar in both groups \[[@R21]\].

Prosthetic Infections
---------------------

A total of seven studies evaluated biomarkers for infection of the prosthesis following knee or hip arthroplasty (summarized in Table **[3](#T3){ref-type="table"}**). Three studies, Rafiq *et al*. \[[@R22]\], Galdbert *et al*. \[[@R23]\], and Frank *et al*. \[[@R24]\] evaluated markers for specific infections of prosthetic joints and four studies evaluated diagnostic biomarkers for prosthetic infections.

### C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR):

Three separate studies \[[@R25]-[@R27]\] each found significantly higher CRP and ESR levels in patients infected prosthetic joints compared to aseptic revisions. Spangehl *et al*. \[[@R28]\] prospectively analyzed patients undergoing hip revisions and noted a sensitivity of 0.96 and specificity of 0.92 for CRP levels \>10 mg/L for infected versus aseptic revisions. For ESR\>30, the respective sensitivity was 0.82 and specificity, 0.85.

### IL-6:

Two studies \[[@R25],[@R26]\] each noted significantly higher levels of serum IL-6 in infected prosthetic joints when compared to aseptic joints undergoing revision arthroplasty.

### Other cytokines:

Bottner *et al*. \[[@R26]\] noted elevated levels of serum TNF-α and procalcitonin in patients with infected prosthetic joints compared to aseptic prosthetic revisions.

### Synovial fluid markers:

Nilsdotter *et al*. \[[@R27]\] noted significantly higher synovial fluid concentrations of TNF-α, IL-1β, and IL-6 in those with infected prosthetic hip joints when compared to aseptic controls.

### Bacterial markers:

Galdbert *et al*. \[[@R23]\] evaluated bacterial genes from S*taphylococcus epidermidis*strains cultured from prosthetic infections as compared to *S. epidermidis*strains from skin flora of healthy controls. They found significantly greater frequency of biofilm production and the ica A operon in infected prostheses. In contrast, Frank *et al*. \[[@R24]\] found no difference in frequency of the ica A operon in coagulase-negative staph species cultured from prosthetic infections in comparison to strains obtained from prosthetic joints without evidence of infection.

Rafiq *et al*. \[[@R22]\] reported significantly elevated titers of IgG to cellular lipoteichoic acid in patients with prosthetic joint infections as compared to patients with osteoarthritis or closed fractures. IgM titers were similar between these groups.

OTHER OUTCOMES
==============

Pain/Stiffness
--------------

Hall *et al*. \[[@R29]\] found a significant correlation between peak CRP levels post-operatively and pain at time of discharge as well as between peak IL-6 levels post-operatively and time to be able to ambulate 10 and 25m following hip arthroplasty. No significant correlations were found between CRP or IL-6 levels post-operatively to 1 and 6 month Western Ontario and McMaster universities osteoarthritis index (WOMAC) values, a measure of arthritis-related disability.

Wozniak *et al*. \[[@R30]\] prospectively found significantly higher nitrous oxide (NO) production from stimulated peripheral neutrophils 2 months and 2-3 years post-operatively in patients with pain compared to patients without pain following primary knee or hip arthroplasty.

Heterotopic Ossification
------------------------

Wilkinson *et al*. \[[@R31]\] noted significantly greater levels of C-telopeptide of type-I collagen, osteocalcin, and N-terminal propeptide of type-I procollagen in patients who developed heterotopic ossification at 26 weeks when compared to those without ossification. No differences were noted in bone ALP, urinary cross-linked N-telopeptide of type-I collagen, and urinary free deoxypridinoline.

Polyethyelene Wear
------------------

Messieh *et al*. \[[@R32]\] noted a significant correlation between synovial lactate dehydrogenase (LDH) levels and polyethylene wear in eleven patients undergoing revision knee arthroplasty.

Hospital Outcomes
-----------------

Ackland *et al*. \[[@R33]\] prospectively noted patients with a preoperative CRP \>3mg/L had a significantly longer mean hospital stay as compared to those with CRP \<3 mg/L (7.5 *vs*6.0 days, respectively) following knee or hip arthroplasty.

DISCUSSION
==========

This systematic review of biomarkers in arthroplasty summarized the findings from 30 studies of clinical outcomes following knee and/or hip arthroplasty. Despite the enormous success rates of knee and hip arthroplasties, patients may face a number of potential complications post-operatively and during long-term follow-up, including periprosthetic osteolysis, implant loosening, and joint infections. Diagnostic and prognostic biomarkers have the potential to provide an early, accurate, and noninvasive diagnosis of these undesired outcomes as well as help design interventions to prevent some of these complications.

The most frequently studied arthroplasty outcomes with regards to biomarkers were osteolysis and prosthesis loosening. Osteolysis and subsequent aseptic joint loosening is the most common reason for joint revision in hip arthroplasty in the United States.

In our review of the published literature, only cross-linked Ntelopeptides of type I collagen (NTX-1) (serum or urine) was significantly associated with loosening/osteolysis, in more than two studies with appropriate controls (without loosening/osteolysis and/or healthy controls) \[[@R4],[@R9],[@R11],[@R12]\]. Von Schewelov *et al*. found an insignificant difference between NTX-1 levels in patients with presence of osteolysis when compared to controls (p = 0.06), though became significant after adjustment for age, gender, and time after surgery.

Serum cytokines, such as serum IL-1 *β* or TNF-*α*, that have been suspected to be associated with development of osteolysis and loosening \[[@R35]-[@R38]\] had inconsistent associations with loosened prostheses \[[@R14],[@R15]\] and no association with osteolysis \[[@R7],[@R8]\]. We postulate that this may be due to lack of well-designed studies rather than lack of association. A significant immunological response occurs in the periprosthetic tissue in many patients with prosthetic loosening, and it has been thought that this inflammatory process may contribute to the development of osteolysis and aseptic loosening \[[@R35]-[@R38]\]. Other biomarkers for osteolysis or prosthesis loosening were either studied by single studies or had inconsistent or insignificant differences.

Prosthetic infections lead to significant morbidity, are difficult to diagnose, and may lead to significant disability. CRP and ESR, both of which are currently used clinically in the diagnosis and follow-up of patients with prosthetic joint infections, were consistently found to be significantly elevated in septic prosthetic joints as compared to aseptic joint revision controls in a number of studies \[[@R25]-[@R28]\]. Interleukin-6 was consistently found to be elevated in septic prostheses as compared to aseptic revision controls \[[@R25],[@R26]\].

A number of other arthroplasty outcomes included in this review, such as heterotopic ossification, pain following arthroplasty, post-operative hospital outcomes, and polyethylene wear, were evaluated only by one or two studies. Because of this, it is difficult to make adequate assessments for there potential use as biomarkers for these outcomes.

This review had a number of limitations, mostly related to limitations of the included studies. The large variability of the biomarkers measured in the included studies with only a few studies replicating the results for each biomarker in more than one study/population, limited our ability to draw conclusions for most biomarkers. The majority of the included studies were case control studies with small sample sizes, with half of the included studies containing \<50 patients. A number of these studies measured multiple biomarkers at multiple outcomes, making them prone to type I error, i.e., finding a positive result just by chance. Well-designed studies of larger, welldefined cohorts are needed to improve our understanding of the utility of these biomarkers in predicting arthroplasty outcomes.

In conclusion, this review evaluated 30 studies that measured different biomarkers for knee and hip arthroplasty outcomes. While a few biomarkers -- namely cross-linked N-telopeptides of type I collagen for prosthesis loosening or osteolysis and CRP, ESR, and IL-6 for infected prostheses -- were found consistently significantly different from control groups in the included studies, most biomarkers lack the evidence to be considered adequate markers for the arthroplasty outcomes at the present time. However, this is an exciting area of research that has the potential to impact and improve arthroplasty outcomes. Further studies are necessary, likely with larger study populations and longer prospective follow-up, to determine which of these biomarkers will have clinical application in diagnosis and/or prognosis of arthroplasty outcomes.
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Search strategy for Systematic Review Performed in 2007 (Updated in July 2008)
==============================================================================

Database: Ovid MEDLINE(R) \<1950 to July Week 4 2007\>

Search Strategy:

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Biological Markers/ or biomarkers.mp. (79469)exp Arthroplasty, Replacement, Knee/ or exp Arthroplasty, Replacement/ or exp Arthroplasty, Replacement, Hip/ or exp Arthroplasty/ or exp Arthroplasty, Replacement, Finger/ or exp Joint Prosthesis/ or arthroplasty.mp. (39802)1 and 2 (125)limit 3 to english language (105)

Summary of the Included Studies
===============================

  Study                Study Design/Level of Evidence      Comparisons                                                                                                                                                                                                                                                                                                Outcomes                                                                                                                                                                                           Other Notes
  -------------------- ----------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antonioiu 2000       case control study/Level III        Hip osteolysis (n = 11), hip arthroplasty without osteolysis (n = 8), healthy controls (n = 7), hip osteolysis following alendronate therapy x6 weeks (n = 10)                                                                                                                                             Urinary cross-linked Ntelopeptide of type I collagen;                                                                                                                                              Longer average time from original operation in osteolysis group (8.8yrs) vs. fixed implants (2.4yrs)
  Von Schewelov 2006   case control study/Level III        Hip osteolysis (n = 33); hip arthroplasty without osteolysis (n = 127)                                                                                                                                                                                                                                     urinary cross-linked Ntelopeptide of type I collagen                                                                                                                                               Post-operative time in osteolysis was 73 months vs. 42 months in nonosteolysis group.
  Arabmotlagh 2006     Prospective cohort study/Level II   53 patients with unilateral THA for OA; followed with bone density scans on 2, 4, 6, and 12mos post-op and correlated to marker measured at 3, 6, 16, and 24 weeks post-op.                                                                                                                                Serum C-terminal telopeptide of type I collagen; bone ALP, osteocalcin                                                                                                                             Numerous comparisons from BMD and biomarkers lessen reliability of findings.
  Hernigou 1999        case control study/Level III        Hip osteolysis, \>10yrs postop (n = 6); hip arthroplasty without osteolysis, \>10yrs post-op (n = 10); hip arthroplasty without osteolysis, \<6yrs post-op (n = 6); healthy controls (n = 5)                                                                                                               IL-B, TNF-a, IL-6, CRP                                                                                                                                                                             
  Fiorito 2003         case control study/Level III        Hip osteolysis (n = 8); hip arthroplasty without osteolylsis (n = 10); healthy controls (n = 17)                                                                                                                                                                                                           IL-1B, IL-6, TNF-a, TGF-B, PGE-2, MMP-1, IL-11                                                                                                                                                     
  Schneider 1998       case control study/Level III        Aseptic loosening of hip implant (n = 50); fixed hip implant (n = 50)                                                                                                                                                                                                                                      Bone ALP, osteocalcin, serum C-terminal propeptide of type I procollagen, urine crosslinked N-telopeptide of type I collagen, urine pyridinoline, urine deoxypyridinonline                         
  Savarino 2005        case control study/Level III        Aseptic loosening of hip implant (n = 21), fixed hip implant (n = 18), OA patients at time of primary arthroplasty (n = 17), healthy controls (n = 30)                                                                                                                                                     Serum cross-linked Ntelopeptide of type I collagen, serum C-terminal propeptide of type I procollagen                                                                                              Healthy controls not matched for age or gender and not used in statistical comparisons
  Li 2004              prospective cohort study/Level II   45 patients followed prospectively after TKA; biomarker measured at 1 week and 3, 6, 12, and 24 months post-op; compared to quality of fixation measured by RSA[1](#AP2FN1){ref-type="fn"} -- MTPM[2](#AP2FN2){ref-type="fn"} \>0.2mm represented unstable fixation, \<0.2mm represented stable fixation   serum C-terminal propeptide of type I procollagen; serum cross-linked C-terminal telopeptide of type I collagen; osteocalcin                                                                       A part of an 80 patient randomized prospective study comparing cemented to uncemented fixation of tibial component for TKA, 45 agreed for blood tests; excluded patients without RSA data at 1 or 2 years (5 patients)
  Wilkinson 2003       case control study/Level III        Aseptic loosening of hip implant (n = 26); stable fixation of hip implant (n = 23)                                                                                                                                                                                                                         Bone ALP, serum cross-linked C-terminal telopeptide, osteocalcin, serum N-terminal propeptide of type I procollagen, urine cross-linked N-telopeptide of type I collagen, free deoxypyridinoline   Only provided data for either femoral or pelvic loosening when compared to fixed implants
  Moreschini 1997      case control study/Level III        Aseptic loosened hip prosthesis (n = 9); fixed hip prosthesis (n = 13); OA patients prior to primary arthroplasty (n = 13)                                                                                                                                                                                 Hyaluronic acid, IL-1B, type III procollagen peptide                                                                                                                                               
  Granchi 1998         case control study/Level III        Aseptic loosening of hip prosthesis (n = 35), healthy controls (n = 25)                                                                                                                                                                                                                                    IL-1a, IL-1B, IL-6, GM-CSF, IL-2 receptor, TNF-a                                                                                                                                                   Differentiated failed arthoplasties to those with CrCoMo or TiAIV components
  Hundri-Haspl 2006    case control study/Level III        Large joint implant loosening (n = 50), large joint arthroplasty without loosening (n = 50), candidates for arthroplasty from advanced OA (n = 50), healthy controls (n = 50)                                                                                                                              IL-1B, IL-8, TNF-a                                                                                                                                                                                 Specific type of large joint prostheses not reported
  Streich 2003         case control study/Level III        Aseptic loosening of hip prosthesis (n = 23), fixed hip prosthetic implant (n = 23)                                                                                                                                                                                                                        IL-6, GM-CSF, elastase                                                                                                                                                                             Significantly more males in healthy donors
  Granchi 2006         case control study/Level III        Aseptic loosening of hip implant (n = 36), fixed hip implant (n = 33), severe OA prior to arthroplasty (n = 39), healthy subjects (n = 20)                                                                                                                                                                 Osteoprotegerin, RANKL                                                                                                                                                                             Significantly more males in healthy donors; significantly longer duration for post-op evaluation in loosening (112 mos) vs. stable joint (32 mos)
  Synpniewska 2002     case control study/Level III        aseptic loosening of hip implant (n = 10); primary OA patients undergoing primary arthroplasty (n = 39)                                                                                                                                                                                                    synovial levels: osteocalcin, B-crosslaps, IL-1a, IL-8, IL-10                                                                                                                                      no fixed arthroplasty control group; excluded patients from analysis if missing outcome data
  Kovacik 2000         case control study/Level III        hip implant revisions (n = 20); primary OA patients undergoing primary arthroplasty (n = 7)                                                                                                                                                                                                                synvoial levels: TRAP, IL-1B                                                                                                                                                                       does not specific reasions for hip implant revions
  Nivbrant 1999        case control study/Level III        loose hip prosthesis (n = 38), fixed hip arthroplasty (n = 12); OA patients undergoing primary arthroplasty (n = 38)                                                                                                                                                                                       synovial levels: IL-1B, TNF-a, IL-6                                                                                                                                                                mean time from implantation for loose prosthetics was 9.8yrs vs. 2.8yrs in fixed implant; excluded patients from analysis if missing data; median data only
  Kawasaki 2001        case control study/Level III        loosened hip prosthesis (n = 5), OA patients from primary hip dysplasia (n = 19), osteonecrosis of femoral neck (n = 21)                                                                                                                                                                                   synovial levels: YKL-40                                                                                                                                                                            average age for OA patients was 48 vs. 63 in loosed implant group; median data only
  Nildotter 2007       case control study/Level III        infected hip implants (n = 25), loosened hip implant (n = 60), OA patients undergoing primary arthroplasty (n = 46)                                                                                                                                                                                        synovial levels: lactate, TNFa, IL-1B, IL-6 serum levels: CRP, ESR, IL-6, TNF-a, IL- 1B                                                                                                            no data provided on serum cytokine levels collected; no comparisons to OA control group provided; excluded patients from analysis if missing data
  Bottner 2007         case control study/Level III        septic revision for large joints (n = 21); aseptic revision of large joints (n = 57)                                                                                                                                                                                                                       CRP, ESR, IL-6, TNF-a, procalcitonin                                                                                                                                                               Knee/hip revisions: 5/16 for septic, 23/34 for aseptic
  Frank 2004           case control study/Level III        staph cultures from prosthetic joint infections compared to coag (-) staph cultures from non-prosthetic joint infections                                                                                                                                                                                   icaADBC operon                                                                                                                                                                                     
  Galdbert 2000        case control study/Level III        staph epidermidis strains from prosthetic infections (n = 54), staph epidermidis strains from skin flora from 8 healthy individuals                                                                                                                                                                        ica operon, biofilm production, genes: clfA, atlE, fbe, fnbA, cna                                                                                                                                  
  Di Cesare 2005       case control study/Level III        58 patients undergoing reoperation of hip or knee: 17 patients with septic prosthetic infection; 41 patients without evidence of infection                                                                                                                                                                 CRP, ESR, IL-6                                                                                                                                                                                     
  Rafiq 2000           case control study/Level III        patients with prosthetic infection from gram positive organisms (n = 15), control group of 32 patients -- 21 with closed fracture, 11 with primary OA                                                                                                                                                      IgG and IgG to lipoteichoic acid                                                                                                                                                                   
  Spangehl 1999        prospective cohort study/Level II   prospectively evaluated 178 patients undergoing revision hip replacements                                                                                                                                                                                                                                  determined specificity, sensitivity for CRP, ESR in prosthetic infections                                                                                                                          no specific data provided for comparison analysis; excluded patients from analysis if missing data
  Hall 2001            prospective study/Level II          102 patients undergoing primary THA                                                                                                                                                                                                                                                                        serum levels: norepinephrine, epinephrine, cortisol, IL-6, CRP; pain, function, and WOMAC[3](#AP2FN3){ref-type="fn"} at 1 and 6 months;                                                            
  Wozniak 2004         prospective cohort study/Level II   33 patients undergoing primary TKA or THA due to OA, divided amongst those experiencing pain (n = 8) and no pain (n = 25) after 2-3 years; 14 healthy controls                                                                                                                                             neutrophils isolated from peripheral blood and analyzed for NO production -- at basline, 2 weeks, 2 months, and 2-3 years post-operatively;                                                        no apparent tool for pain assessment provided; 5/8 reporting pain had evidence of loosening
  Messiah 1996         prospective cohort study/Level II   11 patients undergoing revision TKA; ruled out infection;                                                                                                                                                                                                                                                  synovial LDH levels and correlated to presence of polyethyelene wear                                                                                                                               no control group; no apparent standardized method for measurement of polyethyelene wear reported
  Wilkinson 2003       case control study/Level III        20 patients undergoing primary THA or OA; compared development of heterotopic ossification by 26 weeks (n = 9) with those without evidence of such (n = 11)                                                                                                                                                N-terminal propeptide of type- I procollagen, osteocalcin, bone ALP, C-telopeptide of type-I collagen, urine crosslinked N-telopeptide of type-I collagen and free deoxypridinoline                no control group; only 26 weeks followup for development of heterotopic ossification
  Ackland 2007         prospective cohort study/Level II   129 patients undergoing THA or TKA, divided amongst those with hsCRP \>3mg/L (n = 63) and those with hsCRP \<3mg/L (n = 66)                                                                                                                                                                                length of stay, morbid events                                                                                                                                                                      

RSA = radiostereometric analysis

MTPM = the largest three-dimensional translation of the tibial component

WOMAC = Western Ontario and McMaster universities osteoarthritis index

  Level of evidence based on University of Oxford Center for Evidence-based medicine:Level 1: Testing of previously developed diagnostic criteria in series of consecutive patients (with universally applied reference \"gold\" standard); Systematic review of Level-I studies

  Level 2: Development of diagnostic criteria on basis of consecutive patients (with universally applied reference \"gold\" standard); Systematic review of Level-II studies

  Level 3: Study of nonconsecutive patients (without consistently applied reference \"gold\" standard); Systematic review of Level-III studies

  Level 4: Case-control study; Poor reference standard

  Level 5: Expert opinion
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Summary of screening of eligible studies.

  Outcome                                                 Study (Hip, Knee, Both)    Osteolysis   No Osteolysis                                                                                                             Healthy Control                                                                                  
  ------------------------------------------------------- -------------------------- ------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------- -------------------- ----------- ---- -------------------- ------------
  Collagen peptides                                                                                                                                                                                                                                                                                                          
  Urinary cross-linked N-telopeptide of type I collagen   Antonioiu 2000 (hip)       11           NA                                                                                                                        8[A](#T1FN1){ref-type="table-fn"}     NA                   p = 0.002   7    NA                   p = 0.0297
                                                          Von Schewelov 2006 (hip)   33           34 bone collagen equivalents (BCE)/nM creatinine (12)                                                                     127[A](#T1FN1){ref-type="table-fn"}   29 BCE/nM Cr (15)    p = 0.06                              
  Serum C-terminal telopeptide of type I collagen         Arabmotlagh 2006 (hip)     53           Significant correlation found between bone mineral density loss in ROI 7 at 1 year with week 3 CTX-1 values (p = 0.002)                                                                                                    
  Chemokines, Cytokines & other                                                                                                                                                                                                                                                                                              
  Interleukin (IL)-1β                                     Fiorto 2003 (hip)          8            2.15pg/ml (1.37)                                                                                                          10[A](#T1FN1){ref-type="table-fn"}    2.26pg/ml (0.89)     p = 0.96    17   2.02pg/ml (1.25)     p = 0.79
                                                          Hernigou 1999 (hip)        6            "Undetectable"                                                                                                            10[B](#T1FN2){ref-type="table-fn"}    NA                   NA          5    "undetectable"       NA
  Tumor Necorsis Factor-α                                 Fiorto 2003 (hip)          8            4.32pg/ml (5.2)                                                                                                           10[A](#T1FN1){ref-type="table-fn"}    3.84pg/ml (1.13)     p = 0.62    17   3.42pg/ml (2.12)     p = 0.95
                                                          Hernigou 1999 (hip)        6            "undetectable"                                                                                                            10[B](#T1FN2){ref-type="table-fn"}    NA                   NA          5    "undetectable"       NA
  IL-6                                                    Fiorto 2003 (hip)          8            2.86pg/ml (1.95)                                                                                                          10[A](#T1FN1){ref-type="table-fn"}    4.58pg/ml (4.02)     p = 0.24    17   3.88pg/ml (2.72)     p = 0.36
                                                          Hernigou 1999 (hip)        6            41pg/ml (17)                                                                                                              10[B](#T1FN2){ref-type="table-fn"}    22pg/ml (6.7)        p = 0.002   5    NA                   NA
  IL-11                                                   Fiorto 2003 (hip)          8            0pg/ml (0)                                                                                                                10[A](#T1FN1){ref-type="table-fn"}    1.22pg/ml (2.57)     p = 0.27    17   18.69pg/ml (10.55)   p = 0.001
  transforming growth factor (TGF)-β                      Fiorto 2003 (hip)          8            23175pg/ml (8774)                                                                                                         10[A](#T1FN1){ref-type="table-fn"}    21120pg/ml (13657)   p = 0.50    17   23615pg/ml (10681)   p = 0.88
  matrix metalloproteinase-1 (MMP-1)                      Fiorto 2003 (hip)          8            3.69pg/ml (1.75)                                                                                                          10[A](#T1FN1){ref-type="table-fn"}    4.10pg/ml (1.44)     p = 0.50    17   3.31pg/ml (1.7)      p = 0.52
  prostaglandin E-2 (PGE-2)                               Fiorto 2003 (hip)          8            1330pg/ml (1097)                                                                                                          10[A](#T1FN1){ref-type="table-fn"}    2021pg/ml (1046)     p = 0.14    17   2893pg/ml (782)      p = 0.005
  Bone Alkaline Phosphatase (ALP)                         Arapmotlagh 2006 (hip)     53           No significant correlation found between bone mineral density loss in ROI 7 at 1 year with bone ALP values                                                                                                                 
  Osteocalcin                                             Arapmotlagh 2006 (hip)     53           No significant correlation found between bone mineral density loss in ROI 7 at 1 year with osteocalcin values                                                                                                              
  C-reactive protein                                      Hernigou 1999 (hip)        6            10mg/L (2.4)                                                                                                              10[B](#T1FN2){ref-type="table-fn"}    7.7mg/L (2.8)        p = 0.135   5    NA                   NA

Arthroplasty without osteolysis.

Arthroplasty without osteolysis, \>10 years post-op.

ROI = region of interest.

###### 

Summary of Biomarkers for Loosening of Prosthesis

  --
  --

###### 

Summary of Biomarkers for Infected Prostheses

  --
  --
